secwatch.observer — SEC 8-K summary
======================================

Issuer:     Contineum Therapeutics, Inc. (CTNM)
CIK:        0001855175
Form:       8-K
Filed at:   2024-04-09T23:59:59+00:00
Accession:  0001193125-24-090917
Event type: other
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Contineum Therapeutics adopts amended charter and bylaws upon IPO closing
-------------------------------------------------------------------------

- Authorized 200M Class A common and 20M Class B common shares, plus 10M undesignated preferred.
- Classified board with staggered three-year terms; directors removable only for cause with 66 2/3% vote.
- Exclusive forum: Delaware Chancery for derivative/breach claims; federal courts for Securities Act claims.
- Stockholders cannot act by written consent or call special meetings; new procedures for proposals and nominations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855175/000119312524090917/0001193125-24-090917-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855175/000119312524090917/d811673d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-090917

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer